A Phase IIb multicenter, randomized, double-blind, placebo-controlled, dose-range study to assess the efficacy and safety of GIA632 in participants with moderate to severe cutaneous lichen planus, followed by an extension period
Cutaneous lichen planus is an uncomfortable, non-contagious skin condition that causes an itchy, bumpy, reddish-purple rash. For many people, standard treatments do not bring enough relief. This clinical trial is evaluating an experimental medicine known as GIA632 to see if it can calm skin inflammation and soothe severe itching. The trial is open to adults aged 18 and over with moderate to severe lichen planus. Participants will be randomly chosen to receive either GIA632 at one of several doses or a placebo, which looks the same but contains no active medicine. Neither you nor the doctors will know which you are taking during the first 16 weeks. Doctors will track changes in your skin and itch levels at regular clinic visits. An extension period may allow for further treatment. The goal is to see if GIA632 is safe, effective, and well tolerated.
At a glance
What is this study about?
Cutaneous lichen planus happens when your body's immune system mistakenly attacks cells in your skin. This causes patches of shiny, raised, reddish-purple bumps that can be intensely itchy and painful. Because the condition can last for months or years and current creams or tablets do not always work, living with it can be challenging.
This Phase II clinical trial is testing an investigational drug named GIA632. Researchers want to discover if this medicine can help heal the rash and stop the itch. They are also testing different doses to find the safest and most effective amount to give to patients in the future.
To make sure the results are fair and reliable, the study compares GIA632 to a placebo (a dummy treatment). By taking part, participants help doctors learn whether this new drug could become a helpful future treatment option for people struggling with severe skin lichen planus.
Key takeaways
- Tests an experimental medicine called GIA632 for moderate to severe skin lichen planus.
- Compares different amounts of the drug against a dummy treatment (placebo).
- Main study period lasts 16 weeks, with regular clinic appointments to monitor progress.
- Main goals are to clear skin spots, reduce severe itching, and check medicine safety.
- Taking part is completely voluntary and you can leave at any time.
Who may be eligible?
This trial is for adults aged 18 and older who have been diagnosed with cutaneous lichen planus. Your skin condition must currently be moderate to severe, meaning the rash covers a noticeable area and causes meaningful discomfort.
Both men and women may take part. However, you will need to undergo health checks to make sure the treatment is safe for you. People with certain serious medical conditions, active infections, or those taking specific medications that affect the immune system may not be able to participate.
The study doctor will review your full medical history and current skin treatments to decide whether this trial is a suitable and safe match for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or over.
- I have been diagnosed with cutaneous lichen planus on my skin.
- My skin condition is currently moderate to severe.
- I am able and willing to attend regular clinic check-ups over several months.
- I am comfortable with the possibility of receiving a placebo during the study.
What does participation involve?
If you decide to join, you will first visit the clinic for screening tests, such as blood checks and a skin examination, to confirm your eligibility. If accepted, you will be randomly assigned to take either GIA632 (at a specific dose) or a placebo. The main phase lasts 16 weeks. During this time, you will visit the hospital or clinic at set times (such as weeks 4, 8, 12, and 16). At each visit, doctors will assess your skin, ask you to score your daily itch, check for any side effects, and take routine health measurements. After 16 weeks, you may be invited to continue into an extension period for longer-term monitoring and treatment.
Potential risks and benefits
Locations (6)
- —UnverifiedItaly
- —UnverifiedNetherlands
- —UnverifiedPoland
- —UnverifiedGermany
- —UnverifiedSpain
- —UnverifiedFrance
Common questions
What is a placebo?
A placebo looks identical to the real medicine but contains no active drug. It helps researchers clearly see if changes in health are genuinely caused by the study drug.
Can I choose to get the real medicine instead of the placebo?
No. A computer randomly decides who gets GIA632 and who gets the placebo. Neither you nor your doctor can choose or know which one you are taking during the main study.
Is lichen planus contagious?
No. Lichen planus is an inflammatory condition linked to the immune system. You cannot catch it from someone or pass it on to others.
Do I have to pay for the study treatment?
No. All trial medications, specialist visits, and medical tests are provided free of charge. Travel expenses to and from the clinic are often covered as well.
What happens if I want to stop taking part?
You can leave the study at any time, for any reason. Your decision will not change the standard medical care or treatment you receive from the NHS.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.